Bile acid disease: the emerging epidemic 

Oduyebo I & Camilleri M. Curr Opin Gastroenterol 2017;33:189–195.

Short summary

Type 2 (primary) bile acid diarrhoea (BAD) is associated with increased bile acid production and occurs in nearly 30% of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Primary BAD is associated with disorders of serum fibroblast growth factor 19 (FGF-19) which results in excess bile acid synthesis by hepatocytes. This leads to higher concentrations of bile acids in the colon and increased faecal bile acid loss.

The tauroselcholic (75selenium) acid (SeHCAT) test is the most commonly used test for the diagnosis of BAD. A retention of SeHCAT of less than 10% is...

Register to

Job number: JB57410GBw(1) Date of Preparation: June 2020

Search Tags
bile acid diarrhoea bad 75sehcat gastrointestinal symptoms

Download this file

You must be a registered user to download this files.

You must be registered to
to view or download these files

Register Now

How common is bile acid diarrhoea (BAD)?
Professor David S. Sanders 

How common is bile acid diarrhoea (BAD)?
Professor David S. Sanders 

Professor Sanders argues that many patients presenting with irritable bowel syndrome (IBS) have underlying diseases. He explores a series of studies that suggest approximately 25% of patients presenting with IBS symptoms have BAD as the underlying cause. 

Read More

Sign up to receive our quarterly update & training invites.

A source for healthcare professionals to access the latest data and information on the diagnosis, treatment and management of patients with gut related disorders

Are you a healthcare professional?

This educational website is developed by GE Healthcare for educational purposes. The information contained within this website is intended for healthcare professionals. By entering this website you are confirming that you are a healthcare professional.

Enter the website

This link opens another website that is not under the review or control of GE Healthcare Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.